The Global Midwives' Hub is an online resource that allows for knowledge sharing between users, data visualization tools and improved data literacy to support midwives advocate for the midwifery profession in their country and/or region.
This International Council of Nurses (ICN) fact sheet highlights COVID-19's impact on nurses and other health care workers ahead of International Nurses Day 2021.
This International Council of Nurses (ICN) fact sheet highlights stress and burnout in the nursing profession ahead of International Nurses Day 2021.
This International Council of Nurses (ICN) fact sheet highlights global nurse shortages and retention issues ahead of International Nurses Day 2021.
Resources and knowledge sharing for connecting and strengthening civil society organizations (CSOs), networks, and support organizations worldwide.
Success Story: LBNM Launches New Policies and Strengthens Capacity through HRSA-funded RRHO Project Partner EngagementResilient & Responsive Health Organizations (RRHO), 2021
The Resilient and Responsive Health Organizations (RRHO) project builds the capacity of diverse institutions or “impact partners” that include schools of medicine, midwifery and nursing, professional associations, and government ministries that contribute to improving the quality of health professional education in Liberia, Sierra Leone, and the Democratic Republic of Congo. This RRHO success story describes RRHO's capacity development approach and support to the Liberian Board for Nursing and Midwifery (LBNM).
Rapid Adaptation of HIV DSD Program Design in Response to COVID-19: Results from 14 Countries in Sub-Saharan AfricaICAP, 2020
As the COVID-19 pandemic spread to Africa, CQUIN network countries made significant policy modifications to their differentiated service delivery (DSD) models to protect recipients of care and health care workers and to enhance program resilience. The most common adaptation was the expansion of multi-month dispensing (MMD) to decrease health facility visit frequency. Ten countries expanded MMD eligibility, including four that waived requirements for HIV viral load suppression for people on ART, six that newly permitted MMD for people initiating antiretroviral therapy (ART). This poster describes rapid adaptation of HIV differentiated service delivery program design in response to COVID-19: results from 14 countries in sub-Saharan Africa.
In 2020, the global response to HIV showed inequitable progress across countries and was rocked by the COVID-19 pandemic. This document is meant to assist U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) teams to identify successful and innovative approaches for epidemic control of HIV that can be applied flexibly across the cascade. The challenges presented by COVID-19 led to rapid adaptations and advancements in several strategies, all of which will have tremendous value for epidemic control even after the COVID-19 pandemic subsides. In this document, some strategies are noted as “hot approaches,” meaning they are well suited to meeting current program challenges at this critical juncture.
Roll-out of generic dolutegravir-based HIV treatment regimens continues at a pace worldwide. At the end of 2018, an estimated 3·9 million people with HIV in 61 low-income and middle-income countries (LMICs) had access to generic dolutegravir and the preferred first-line combination of tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD). In 2019, estimates suggest 6·9 million people had access to generic dolutegravir and 82 LMICs were reported to be transitioning to dolutegravir-based treatment regimens. By mid-2020, according to WHO, transition to dolutegravir has now been implemented in 100 LMICs. However, UNAIDS estimate up to 32 countries have not yet recommended dolutegravir as first-line therapy, and 20 countries that added dolutegravir-based regimens to their national guidelines have yet to begin procurement. This editorial recommends that as the WHO-recommended first-line treatment, every country should aim to offer dolutegravir as therapy for people with HIV, while adequate surveillance continues to detect and manage any adverse events. All programmes must have access to a range of treatment options and providers and patients should be able to make informed choices from the best options.
USAID's Supply Chain for Health team has put together an antiretroviral (ARV) planning tool to help countries consider their ARV procurement and supply chain planning for implementing i. “treat all” and ii. longer ART refills, also known as multi-month scripting (MMS). By inputting the i. the total number of newly identified HIV positive patients starting ART and ii. the number of stable patients (eligible for MMS) the tool determines the number of ART treatments needed to implement “treat all” and MMS over a three-year period. Countries can then identify the initial "bump" of additional ARV treatments needed in year one. In addition, it will enable countries to note how many additional ARV treatments are needed in years 2 and 3. Finally, the tool provides countries with an estimate of the number of ARVs needed to transition a country’s care and treatment programmes from monthly prescribing to longer refills (2-, 3-, 4-, or 6-months) in MMS programmes.